View Exam | PowerPak

1. A classic disabling symptom of PD is:

A. Numbness and tingling in lower extremities B. Bradykinesias C. Migraine-type headaches D. Dystonia

2. Monoamine oxidase-B inhibitors are given to:

A. Boost acetylcholine levels in the brain B. Prolong the effects of dopamine C. Block dopamine-3 receptors D. Prevent the progression of PD

3. Why delay the use of levodopa in younger patients?

A. It does not reduce symptoms in younger patients. B. It accelerates disease progression. C. It prevents later use of dopamine antagonists. D. It is associated with motor complications and dyskinesias.

4. A 68-year-old woman with PD, who is taking carbidopa/levodopa and a dopamine antagonist, has developed “wearing-off” motor complications. What is an appropriate management strategy?

A. Adding an monoamine oxidase-B inhibitor B. Discontinuing the dopamine antagonist C. Tapering the levodopa dose D. Switching to a less frequent levodopa dose

5. A 50-year-old man with PD has just begun taking carbidopa/levodopa in addition to his monoamine oxidase-B (MAO-B) inhibitor. He develops nausea and dizziness. What is an appropriate management strategy?

A. Eliminating the MAO-B inhibitor B. Tapering the dose of the MAO-B inhibitor C. Reducing the dose of carbidopa D. Increasing the dose of carbidopa

6. Which statement about PD therapy is FALSE?

A. Dopamine agonists can be effective first-line therapies. B. Monoamine oxidase-B inhibitors can be effective first-line therapies. C. Catechol-O-methyl transferase inhibitors are effective in treating dyskinesias. D. Anticholinergics can be combined with dopamine agonists.

7. Which of the following PD therapies is associated with insomnia due to a metabolite?

A. Pramipexole B. Ropinirole C. Selegiline D. Rasagiline

8. A feature that distinguishes drug-induced secondary parkinsonism from classic idiopathic PD is:

A. Rapid loss of smell B. Rapid onset of bilateral symptoms C. Resting unilateral tremor D. Dyskinesias

9. Catechol-O-methyltransferase inhibitors:

A. Must always be used with carbidopa/levodopa B. Must never be used with monoamine oxidase-B inhibitors C. Are contraindicated in patients with depression D. Exacerbate “wearing off” motor complications

10. Which of the following is NOT a common nonmotor symptom/sign of PD?

A. Osteoporosis B. Constipation C. Depression D. Psychosis

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. A classic disabling symptom of PD is:

2. Monoamine oxidase-B inhibitors are given to:

3. Why delay the use of levodopa in younger patients?

4. A 68-year-old woman with PD, who is taking carbidopa/levodopa and a dopamine antagonist, has developed “wearing-off” motor complications. What is an appropriate management strategy?

5. A 50-year-old man with PD has just begun taking carbidopa/levodopa in addition to his monoamine oxidase-B (MAO-B) inhibitor. He develops nausea and dizziness. What is an appropriate management strategy?

6. Which statement about PD therapy is FALSE?

7. Which of the following PD therapies is associated with insomnia due to a metabolite?

8. A feature that distinguishes drug-induced secondary parkinsonism from classic idiopathic PD is:

9. Catechol-O-methyltransferase inhibitors:

10. Which of the following is NOT a common nonmotor symptom/sign of PD?

« Return to Activity

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. A classic disabling symptom of PD is:

2. Monoamine oxidase-B inhibitors are given to:

3. Why delay the use of levodopa in younger patients?

4. A 68-year-old woman with PD, who is taking carbidopa/levodopa and a dopamine antagonist, has developed “wearing-off” motor complications. What is an appropriate management strategy?

5. A 50-year-old man with PD has just begun taking carbidopa/levodopa in addition to his monoamine oxidase-B (MAO-B) inhibitor. He develops nausea and dizziness. What is an appropriate management strategy?

6. Which statement about PD therapy is FALSE?

7. Which of the following PD therapies is associated with insomnia due to a metabolite?

8. A feature that distinguishes drug-induced secondary parkinsonism from classic idiopathic PD is:

9. Catechol-O-methyltransferase inhibitors:

10. Which of the following is NOT a common nonmotor symptom/sign of PD?

« Return to Activity

Customers who Purchased
this Activity also Purchased